Compare Marriott International Inc (MAR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs TG Therapeutics Inc — how do they compare? Marriott International Inc trades at $365 (market cap $96.76B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Marriott International Inc is far larger — about 11.7× TG Therapeutics Inc's market cap, and Marriott International Inc pays a 0.8% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MAR | TGTX | |
|---|---|---|
Market Cap | $96.76B | $8.26B |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $59.06 |
52-Week Low | $255.35 | $26.39 |
Enterprise Value | $113.71B | $8.50B |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $367.81, up 0.43% on the day, with a bearish technical signal and mixed earnings history. The company reported 2025 revenue of $26.19B and net income of $2.60B, with a P/E of 38.42 and P/B of 443.63 indicating high valuation. Recent news includes strategic partnerships and the upcoming Q2 2026 earnings report on August 3, 2026.
The outlook is cautious due to high valuation and bearish technicals, but analyst consensus suggests a 5.6% upside to the $388.33 price target. Risks include rising debt-to-asset ratio (58.83% in 2025) and competitive pressures, while opportunities lie in travel demand growth and loyalty program strength.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
